Supplemental material
Open access
1,509
Views
2
CrossRef citations to date
0
Altmetric
Original Research
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France
Mark Oppea Axentiva Solutions, Barcelona, SpainView further author information
, Bogdan Muresanb IQVIA, Health Economics and Outcomes Research, Amsterdam, NetherlandsView further author information
, Katie Chanc IQVIA, EMEA HE Real-World Methods & Evidence Generation, London, UKView further author information
, Xenia Raduc IQVIA, EMEA HE Real-World Methods & Evidence Generation, London, UKView further author information
, Bob G. Schultzd Takeda Pharmaceuticals U.S.A., Inc, US Medical Affairs, Value & Evidence Generation, Lexington, MA, USAhttps://orcid.org/0000-0002-7023-8378View further author information
, Robin S. Turpine Takeda Pharmaceuticals U.S.A., Inc, US Value Evidence, Bannockburn, IL, USAView further author information
, Arnaud Nucitf Takeda France S.A.S, Health Economics - Patient Value & Access, Paris, FranceView further author information
& Elisabetta Fenug Takeda Pharmaceuticals International AG, Global Health Economics, Zurich, SwitzerlandCorrespondence[email protected]
View further author information
show allView further author information
Pages 205-213
|
Received 09 Nov 2021, Accepted 15 Dec 2022, Published online: 05 Jan 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.